1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project)
(
- Contribution to journal › Article
-
Mark
European Task Force on Atopic Dermatitis : position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics
(
- Contribution to journal › Letter
-
Mark
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts
(
- Contribution to journal › Letter
- 2020
-
Mark
Development and initial testing of a new instrument to measure the experience of eczema control in adults and children : Recap of atopic eczema (RECAP)
(
- Contribution to journal › Article
-
Mark
TREatment of ATopic eczema (TREAT) Registry Taskforce : protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema
(
- Contribution to journal › Article
- 2019
-
Mark
European task force on atopic dermatitis position paper : treatment of parental atopic dermatitis during preconception, pregnancy and lactation period
(
- Contribution to journal › Article
- 2018
-
Mark
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
(
- Contribution to journal › Article
- 2017
-
Mark
Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials : A Harmonising Outcome Measures for Eczema (HOME) statement
(
- Contribution to journal › Article
-
Mark
Evaluation of the measurement properties of symptom measurement instruments for atopic eczema : A systematic review
(
- Contribution to journal › Article
- 2016
-
Mark
Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
(
- Contribution to journal › Article